To include your compound in the COVID-19 Resource Center, submit it here.

CMS: Avastin coverage same, for now

After an FDA advisory panel voted this week to withdraw accelerated approval for Avastin bevacizumab to treat first-line HER2-negative metastatic

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE